טוען...
PRSS contributes to cetuximab resistance in colorectal cancer
Cetuximab improves the survival of patients with metastatic colorectal cancer. The main limitation is primary and secondary resistance, the underlying mechanism of which requires extensive investigation. We proved that PRSS expression levels are significantly negatively associated with the sensitivi...
שמור ב:
| הוצא לאור ב: | Sci Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Association for the Advancement of Science
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6938705/ https://ncbi.nlm.nih.gov/pubmed/31911942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aax5576 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|